Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- Myfortic (mycophenolic acid)
- ublituximab
Interactions between your drugs
mycophenolic acid ublituximab
Applies to: Myfortic (mycophenolic acid), ublituximab
Using ublituximab together with mycophenolic acid may increase the risk of serious infections. Talk to your doctor if you have any questions or concerns. Of particular concern is an infection known as progressive multifocal leukoencephalopathy (PML), which is a rare but serious viral infection of the brain that may lead to disability and death. Your doctor may already be aware of the risks but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications. Let your doctor know if you develop signs and symptoms of infection such as fever, chills, sore throat, shortness of breath, blood in phlegm, weight loss; yellow skin, severe fatigue, diarrhea, vomiting, body aches; and pain or burning during urination. Also, seek immediate medical attention if you experience progressive weakness on one side of the body, clumsiness of limbs, disturbance of vision, confusion, or changes in thinking, memory, and personality, as these may be early symptoms of PML. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
mycophenolic acid food
Applies to: Myfortic (mycophenolic acid)
Take mycophenolic acid on an empty stomach 1 hour before or 2 hours after a meal unless otherwise directed by your doctor. Food may reduce the absorption of mycophenolic acid. This will make it easier for your body to absorb the medication. Do not crush, chew, or cut the tablets. The tablets have a special coating to protect the stomach from irritation.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Nulojix
Nulojix (belatacept) is used in combination with other medications to prevent organ rejection after ...
Afinitor
Afinitor prevents the growth of cancer cells and is used to treat advanced kidney cancer. Learn ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Afinitor Disperz
Afinitor Disperz is used for subependymal giant cell astrocytoma, tuberous sclerosis complex
Arava
Arava (leflunomide) is used to treat the symptoms of rheumatoid arthritis and help reduce joint ...
Arzerra
Arzerra is used to treat chronic lymphocytic leukemia (CLL), usually in combination with other ...
Aubagio
Aubagio (teriflunomide) is used to reduce flare-ups in people with relapsing multiple sclerosis ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.